INE416D01022
INE416D01022
BLISS GVS PHARMA LTD.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2026 | 2025 | Change % |
|---|---|---|---|
| Total Revenue | 9.206.389.000 | 8.017.955.000 | 14.8% |
| Cost of Revenue | 4.250.645.000 | 4.136.882.000 | 2.7% |
| Gross Profit | 4.955.744.000 | 3.881.073.000 | 27.7% |
| 3.364.870.000 | 2.903.496.000 | 15.9% | |
| Operating Income | 1.590.874.000 | 977.577.000 | 62.7% |
| Pretax Income | 1.895.892.000 | 1.256.392.000 | 50.9% |
| Net Income Common Stockholders | 1.291.292.000 | 842.993.000 | 53.2% |
| -- | -- | -- | |
| -- | -- | -- |